Suchergebnisse - "Frisell, Thomas"

PubPharm (12)

1

Genome-wide investigation of persistence to treatment with methotrexate in early rheumatoid arthritis

enthalten in: Rheumatology (Oxford, England) | 2023

von Öberg Sysojev, A. | Saevarsdottir, S. | Diaz-Gallo, L. | +14

ErratumIn: Rheumatology (Oxford). 2023 Oct 12;:. - PMID 37830303

2

Do patient-reported measures of disease activity in rheumatoid arthritis vary between countries? Results from a Nordic collaboration

enthalten in: Rheumatology (Oxford, England) | 2022

von Delcoigne, B. | Provan, S. | Hammer, H. | +10

ErratumIn: Rheumatology (Oxford). 2022 Mar 25;:. - PMID 35333334

3

Effectiveness of baricitinib and tofacitinib compared with bDMARDs in RA : results from a cohort study using nationwide Swedish register data

enthalten in: Rheumatology (Oxford, England) | 2022

von Barbulescu, A. | Askling, J. | Chatzidionysiou, K. | +5

4

Short- and longer-term cancer risks with biologic and targeted synthetic disease-modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice

enthalten in: Rheumatology (Oxford, England) | 2022

von Huss, V. | Bower, H. | Wadström, H. | +15

CommentIn: Rheumatology (Oxford). 2022 May 5;61(5):1758-1759. - PMID 34648000

5

Influenza outcomes in patients with inflammatory joint diseases and DMARDs : how do they compare to those of COVID-19?

enthalten in: Annals of the rheumatic diseases | 2022

von Bower, H. | Frisell, T. | Di Giuseppe, D. | +2

6

Effects of the COVID-19 pandemic on patients with inflammatory joint diseases in Sweden : from infection severity to impact on care provision

enthalten in: RMD open | 2021

von Bower, H. | Frisell, T. | di Giuseppe, D. | +26

ErratumIn: RMD Open. 2022 Jan;8(1):. - PMID 35042729

7

Effectiveness of a Second Biologic After Failure of a Non-tumor Necrosis Factor Inhibitor As First Biologic in Rheumatoid Arthritis

enthalten in: The Journal of rheumatology | 2021

von Chatzidionysiou, K. | Hetland, M. | Frisell, T. | +17

8

Response to : 'Inflammatory and non-inflammatory triggers of acute coronary syndromes' by Eyuboglu

enthalten in: Annals of the rheumatic diseases | 2020

von Westerlind, H. | Holmqvist, M. | Ljung, L. | +2

CommentOn: Ann Rheum Dis. 2019 May;78(5):683-687. - PMID 30787006

9

Siblings of patients with rheumatoid arthritis are at increased risk of acute coronary syndrome

enthalten in: Annals of the rheumatic diseases | 2019

von Westerlind, H. | Holmqvist, M. | Ljung, L. | +2

CommentIn: Ann Rheum Dis. 2020 May;79(5):e49. - PMID 30842124

10

Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics

enthalten in: Annals of the rheumatic diseases | 2018

von Frisell, T. | Baecklund, E. | Bengtsson, K. | +4